KNSA 250117 15.00C (KNSA250117C15000) Stock Options, News & Quotes

English
中文繁體
中文简体

Download

Mobile

moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US OptionsDetailed Quotes

KNSA250117C15000

Watchlist

0.00
0.000.00%

15min DelayClose Jan 13 09:30 ET

0.00High0.00Low

Intraday

5D
Daily

No Data

News

Goldman Sachs Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Maintains Target Price $32
Moomoo News14:31 ET · Ratings
Kiniksa Pharma Reports Q4 ARCALYST Revenue Of $121.9M, Cash Balance Of $243.6M
BenzingaJan 13 07:40 ET
Express News | Kiniksa Pharmaceuticals International PLC - Arcalyst 2024 Net Product Rev $416.4 Million, 79% YoY Growth
ReutersJan 13 07:31 ET
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Climbs 3.6% This Week, Taking Three-year Gains to 83%
Simply Wall StJan 6 05:19 ET
Kiniksa Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare Conference
Kiniksa PharmaceuticalsJan 6 00:00 ET
Insider Sale: CHIEF ACCOUNTING OFFICER of $KNSA (KNSA) Sells 9 Shares
Quiver QuantitativeDec 2, 2024 16:46 ET

Comments

TrendTrader

Jul 23, 2024 11:19

Looking for 30

$Kiniksa Pharmaceuticals International (KNSA.US)$

Moomoo AI

Feb 28, 2024 07:16

The share price rise is a fair reaction to the company's revenue growth. More gains could follow if the trend continues. Yet, consider the company's profitability and cash flow before investing.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) Delivers Shareholders Respectable 66% Return Over 1 Year, Surging 4.7% in the Last Week Alone

Moomoo AI

Jan 23, 2024 06:38

Kiniksa Pharmaceuticals' low P/S ratio may be due to its forecast growth being lower than the industry. Shareholders accept this, conceding future revenue probably won't surprise positively. It's hard to see the share price rising strongly soon under these circumstances.

Kiniksa Pharmaceuticals, Ltd.'s (NASDAQ:KNSA) Low P/S No Reason For Excitement

Meltyy

Jan 3, 2024 06:11

Upcoming Ph 2 readouts in Q1 2024…

$Cellectar BioSciences (CLRB.US)$ Phase 2
$Regenxbio (RGNX.US)$ Phase 2
$Leap Therapeutics (LPTX.US)$ Phase 2
$4D Molecular Therapeutics (FDMT.US)$ Phase 2
$Adverum Biotechnologies (ADVM.US)$ Phase 2
$Denali Therapeutics (DNLI.US)$ Phase 2
$EyePoint Pharmaceuticals (EYPT.US)$ Phase 2
$Xencor (XNCR.US)$ Phase 2
$Harmony Biosciences (HRMY.US)$ Phase 2
$Alnylam Pharmaceuticals (ALNY.US)$ Phase 2
$Disc Medicine (IRON.US)$ Phase 2
$Atea Pharmaceuticals (AVIR.US)$ Phase 2
$Allakos (ALLK.US)$ Phase 2...

Moomoo AI

Dec 8, 2023 10:12

Kiniksa Pharmaceuticals' growing cash burn is offset by substantial cash reserves & signs of business growth. The firm can issue shares or borrow cheaply to fund further growth.

We're Not Worried About Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn